Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Danyang Li, Biping Deng, Qinlong Zheng, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 7259.

https://doi.org/10.1182/blood-2025-7259

Published: 2025

Journal Articles

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 672.

https://doi.org/10.1182/blood-2025-672

Published: 2025

Journal Articles

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2025-3708

Published: 2025

Journal Articles

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

Rui Liu, Danyang Li, Zhonghua Fu, Fan Yang, Miaomiao Cao, Lixia Ma, Yuelu Guo, Alex H. Zhang, Biping Deng, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 3706.

https://doi.org/10.1182/blood-2025-3706

Published: 2025

Journal Articles

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

Miaomiao Cao, Hui Shi, Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 5489.

https://doi.org/10.1182/blood-2025-5489

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only